image
Healthcare - Medical - Devices - NASDAQ - US
$ 13.05
-0.685 %
$ 530 M
Market Cap
-19.77
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one RXST stock under the worst case scenario is HIDDEN Compared to the current market price of 13.1 USD, RxSight, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one RXST stock under the base case scenario is HIDDEN Compared to the current market price of 13.1 USD, RxSight, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one RXST stock under the best case scenario is HIDDEN Compared to the current market price of 13.1 USD, RxSight, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RXST

image
$35.0$35.0$30.0$30.0$25.0$25.0$20.0$20.0$15.0$15.0$10.0$10.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
140 M REVENUE
57.09%
-36.9 M OPERATING INCOME
26.41%
-27.5 M NET INCOME
43.52%
-16.9 M OPERATING CASH FLOW
59.26%
-99.3 M INVESTING CASH FLOW
-348.78%
123 M FINANCING CASH FLOW
100.44%
37.9 M REVENUE
-5.77%
-10.7 M OPERATING INCOME
-23.71%
-8.19 M NET INCOME
-37.93%
-8.83 M OPERATING CASH FLOW
-107.32%
20.9 M INVESTING CASH FLOW
1479.92%
-735 K FINANCING CASH FLOW
-24.70%
Balance Sheet RxSight, Inc.
image
Current Assets 294 M
Cash & Short-Term Investments 237 M
Receivables 30 M
Other Current Assets 26.6 M
Non-Current Assets 24.7 M
Long-Term Investments 0
PP&E 23.6 M
Other Non-Current Assets 1.11 M
74.47 %9.43 %8.33 %7.42 %Total Assets$318.6m
Current Liabilities 25.9 M
Accounts Payable 4.54 M
Short-Term Debt 974 K
Other Current Liabilities 20.4 M
Non-Current Liabilities 11.4 M
Long-Term Debt 11.3 M
Other Non-Current Liabilities 127 K
12.17 %54.54 %30.33 %Total Liabilities$37.3m
EFFICIENCY
Earnings Waterfall RxSight, Inc.
image
Revenue 140 M
Cost Of Revenue 41 M
Gross Profit 98.9 M
Operating Expenses 136 M
Operating Income -36.9 M
Other Expenses -9.4 M
Net Income -27.5 M
140m140m120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)140m(41m)99m(136m)(37m)9m(27m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
70.71% GROSS MARGIN
70.71%
-26.34% OPERATING MARGIN
-26.34%
-19.62% NET MARGIN
-19.62%
-9.76% ROE
-9.76%
-8.62% ROA
-8.62%
-12.57% ROIC
-12.57%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis RxSight, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)202020202021202120222022202320232024202420252025
Net Income -27.5 M
Depreciation & Amortization 3.62 M
Capital Expenditures -5.44 M
Stock-Based Compensation 0
Change in Working Capital -9.21 M
Others -16.9 M
Free Cash Flow -22.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets RxSight, Inc.
image
Wall Street analysts predict an average 1-year price target for RXST of $68.1 , with forecasts ranging from a low of $52 to a high of $110 .
RXST Lowest Price Target Wall Street Target
52 USD 298.47%
RXST Average Price Target Wall Street Target
68.1 USD 422.03%
RXST Highest Price Target Wall Street Target
110 USD 742.91%
Price
Max Price Target
Min Price Target
Average Price Target
110110100100909080807070606050504040303020201010Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership RxSight, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
289 K USD 2
6-9 MONTHS
3.05 M USD 2
9-12 MONTHS
1.89 M USD 2
Bought
0 USD 0
0-3 MONTHS
100 K USD 1
3-6 MONTHS
1.01 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
FMS vs. RXST: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or RxSight, Inc. (RXST). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com - 4 days ago
FMS or RXST: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or RxSight, Inc. (RXST). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com - 2 weeks ago
RxSight: Valuation Blowout Creates Opportunity RxSight is a promising growth stock in the medical device sector, focusing on innovative cataract treatments with a large addressable market. Despite a recent decline, RxSight's high margins and scalable technology make it an attractive long-term investment, especially with expected 20% revenue growth in 2025. The stock's valuation has dropped from 20x to 4x trailing sales over the past year, presenting a potential buying opportunity for long-term investors. seekingalpha.com - 1 month ago
RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum ALISO VIEJO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Stifel Virtual Ophthalmology Forum. globenewswire.com - 1 month ago
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. benzinga.com - 1 month ago
RxSight, Inc. (RXST) Q1 2025 Earnings Call Transcript RxSight, Inc. (NASDAQ:RXST ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Oliver Moravcevic - Vice President, Investor Relations Ron Kurtz - President & Chief Executive Officer Shelley Thunen - Chief Financial Officer Conference Call Participants Xuyang Li - Jefferies Patrick Wood - Morgan Stanley Steve Lichtman - Oppenheimer David Saxon - Needham & Company Adam Maeder - Piper Sandler Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Craig Bijou - Bank of America Tom Stephan - Stifel Operator Thank you for standing by. At this time, I would like to welcome everyone to the RxSight First Quarter 2025 Earnings Conference Call. seekingalpha.com - 2 months ago
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates RxSight, Inc. (RXST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.12 per share a year ago. zacks.com - 2 months ago
RxSight, Inc. to Present at the Bank of America Healthcare Conference ALISO VIEJO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference in Las Vegas. globenewswire.com - 2 months ago
RxSight, Inc. (RXST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 months ago
RxSight price target lowered to $17 from $22 at Wells Fargo Wells Fargo lowered the firm's price target on RxSight to $17 from $22 and keeps an Equal Weight rating on the shares following the conference call to discuss the preliminary Q1 2025 sales results and lowered FY25 guidance. The company called out weak LAL volume trends through Q1, especially March, competitive product launches, and recessionary concerns, Wells notes. 09 May https://thefly.com - 3 months ago
​RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade) RxSight posted a sequential revenue decline, revealing cracks in momentum despite earlier signs of profitability. Revised 2025 outlook and lack of expected profitability suggest earlier optimism was premature. The competitive landscape has intensified with new IOL products from Johnson & Johnson and Rayner, challenging RxSight's unique LAL technology. seekingalpha.com - 3 months ago
RxSight, Inc. (RXST) Q1 2025 Preliminary Results Conference Call (Transcript) RxSight, Inc. (NASDAQ:RXST ) Q1 2025 Preliminary Results Conference Call April 3, 2025 8:00 AM ET Company Participants Oliver Moravcevic - VP, IR Dr. Ron Kurtz - Director, Co-President and CEO Shelley Thunen - Assistant Secretary, Co-President and CFO Conference Call Participants Ryan Zimmerman - BTIG Xuyang Li - Jefferies Robert Marcus - JPMorgan Steve Lichtman - Oppenheimer David Saxon - Needham Danielle Antalffy - UBS Operator Thank you for standing by, and welcome to the RxSight conference call. All lines have been placed on mute to prevent any background noise. seekingalpha.com - 3 months ago
8. Profile Summary

RxSight, Inc. RXST

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 530 M
Dividend Yield 0.00%
Description RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Contact 100 Columbia, Aliso Viejo, CA, 92656 https://www.rxsight.com
IPO Date July 30, 2021
Employees 498
Officers Ms. Caroline Vaughn Vice President of Human Resources Mr. Roy Freeman Senior Vice President of Marketing & Professional Relations Dr. Ronald M. Kurtz M.D. Co-President, Chief Executive Officer & Director Mr. Scott Gaines Executive Vice President of Manufacturing & Commercial Operations Mr. Oliver Moravcevic Vice President of Investor Relations Mr. Matt Haller Ph.D. Chief Technology Officer Dr. Ilya Goldshleger Ph.D. Co-President & Chief Operating Officer Ms. Shelley B. Thunen Co-President & Chief Financial Officer Mr. Steve Everly Senior Vice President of Sales of North America Mr. Eric J. Weinberg Co-President & Chief Commercial Officer